The Defense Health Agency awarded a purchase order to Cepheid for $2,523,831.62 on October 1, 2021, with an ultimate completion date of September 30, 2026. Performance is at Fort Hood, Texas. The order covers reagents and related change administration services compatible with Cepheid GeneXpert diagnostic analyzers, including assays for group B streptococcus, invasive viral disease, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Clostridioides difficile, influenza, Streptococcus pyogenes, and influenza/respiratory syncytial virus. The order originated from a Department of the Army Medical Command sources-sought notice issued in May 2021 and carries firm fixed-price terms with no set-aside designation.